Nuclear Dot Pattern on ANA Test: What Few and Multiple Nuclear Dots Mean
Other names: Nuclear Dot Pattern, Nuclear Dot Pattern ANA, ANA Nuclear Dot Pattern, Nuclear Dots ANA, ANA Nuclear Dots, Nuclear Dots ANA Pattern, Nuclear Dot Pattern High, Discrete Nuclear Dots, Discrete Nuclear Dots ANA, ANA Discrete Nuclear Dots, Discrete Nuclear Dots ANA Pattern, Few Nuclear Dots ANA, ANA Few Nuclear Dots, Few Nuclear Dots ANA Pattern, ANA Pattern Few Nuclear Dots, Multiple Nuclear Dots ANA, ANA Multiple Nuclear Dots, Multiple Nuclear Dots ANA Pattern, ANA Pattern Multiple Nuclear Dots, Nuclear Dot Pattern Positive, Positive ANA Nuclear Dots Pattern, ANA Pattern Nuclear Dots, Nuclear Dots, Nuclear Dot, ANA Nuclear Dots Pattern, Nuclear Dot ANA, AC-6 Multiple Nuclear Dots, AC-6 ANA Pattern, AC-7 Few Nuclear Dots, AC-7 ANA Pattern, ICAP AC-6, ICAP AC-7, Nuclear Dot Pattern 1:80, Nuclear Dot Pattern 1:160, Nuclear Dot Pattern 1:320, Nuclear Dot Pattern 1:640, Nuclear Dot 1:320, ANA Nuclear Dot Pattern 1:160, What Does Discrete Nuclear Dots Mean, What is Nuclear Dot Pattern, Nuclear Dot Primary Biliary Cholangitis, Nuclear Dot Pattern PBC, SP100 Antibody ANA, Anti-Sp100, Anti-Sp140, Anti-PML Antibody, Anti-NXP-2 Antibody, Anti-MJ Antibody, PML Protein, SP100, Nuclear Dots Bedeutung (German), Nuclear Dots Pattern Bedeutung (German), ANA Patron Nuclear Dots (Spanish), Anticuerpos Antinucleares Nuclear Dots (Spanish), Nucleaire Patroon Nuclear Dots (Dutch), ANA Pattern Nuclear Dots Meaning, Nuclear Dot Pattern Significance, Nuclear Multiple Nuclear Dots, Nuclear Discrete Nuclear Dots, Cajal Body Pattern ANA, Coilin Antibody ANA, p80-coilin Antibody, SMN Complex Antibody, Nuclear Dot Pattern Autoimmune, ANA Nuclear Dot Pattern Significance, Nuclear Dot Pattern Diseases, What Does Nuclear Dot Pattern Mean, ANA Pattern Nuclear Dot Meaning, Positive ANA Nuclear Dot Pattern High, AMA Negative PBC ANA Pattern, Anti-GP210, Nuclear Envelope ANA Pattern PBC
QUICK ANSWER
The nuclear dot pattern is a specific fluorescence pattern seen on a positive ANA by IFA test. Discrete bright dots appear within cell nuclei under the microscope. There are two main types — and distinguishing between them matters clinically.
| Sub-type | ICAP code | Dots per nucleus | Primary association |
|---|---|---|---|
| Multiple nuclear dots | AC-6 | Classically ~6–20 per cell | Primary biliary cholangitis (PBC); anti-Sp100 and anti-Sp140 antibodies |
| Few nuclear dots | AC-7 | Classically ~1–6 per cell | Low positive predictive value; p80-coilin / SMN complex; often incidental |
Common questions at a glance:
| Question | Short answer |
|---|---|
| What does nuclear dot pattern mean on ANA? | Discrete bright dots within cell nuclei — a specific ANA fluorescence pattern |
| What does "multiple nuclear dots" mean? | ~6–20 dots per nucleus (AC-6); most commonly associated with primary biliary cholangitis |
| What does "few nuclear dots" mean? | ~1–6 dots per nucleus (AC-7); low positive predictive value; often incidental |
| What does "discrete nuclear dots" mean? | Same as nuclear dot pattern — "discrete" describes the sharply defined appearance of the dots |
| What does "nuclear dot pattern high" mean? | A positive nuclear dot pattern with a high titer — the number refers to antibody concentration, not dot count |
| What diseases are associated with nuclear dot pattern? | AC-6: primarily PBC; AC-7: low disease specificity |
WHAT IS THE NUCLEAR DOT PATTERN?
The nuclear dot pattern is one of the recognized ANA fluorescence patterns classified by the International Consensus on ANA Patterns (ICAP). When a blood sample is tested for antinuclear antibodies by indirect fluorescent antibody (IFA) method, the serum is applied to HEp-2 cells on a glass slide. If antinuclear antibodies are present, they bind to specific structures inside the cell nucleus, producing a fluorescence pattern visible under a fluorescent microscope.
The nuclear dot pattern appears as a small number of sharply defined (discrete) bright fluorescent dots located within the nucleus — distinct from the diffuse or granular staining of other ANA patterns. The dots correspond to specific nuclear bodies — compact protein structures inside the nucleus that serve regulatory functions in gene expression, antiviral response, and protein processing.
Why the nuclear dot pattern is distinct from other ANA patterns:
| Pattern | Appearance under microscope | Key distinction from nuclear dots |
|---|---|---|
| Nuclear dot (AC-6/AC-7) | Small number of discrete bright dots within the nucleus | Dots are few and sharply defined |
| Homogeneous | Uniform staining across the entire nucleus | Diffuse — no distinct dots |
| Speckled | Fine or coarse granular staining throughout nucleus | More numerous and less distinct than nuclear dots |
| Nucleolar | Staining concentrated in the nucleolus | Located in nucleolus, not in nuclear body dots |
| Centromere (AC-3) | Many dots at centromere/kinetochore positions — ICAP describes ~40–80 per cell | Many more dots than nuclear dot pattern |
FEW NUCLEAR DOTS VS MULTIPLE NUCLEAR DOTS — THE KEY DISTINCTION
The ICAP nomenclature divides the nuclear dot pattern into two distinct sub-types. The distinction has significant clinical relevance.
AC-6: Multiple Nuclear Dots
| Feature | Details |
|---|---|
| Appearance | Classically ~6–20 discrete dots per cell (ICAP); the lab's pattern call matters more than counting yourself |
| ICAP code | AC-6 |
| Nuclear structure targeted | PML nuclear bodies (also called ND10 bodies) — protein complexes involved in antiviral response, DNA repair, and gene regulation |
| Associated antibodies | Anti-Sp100 (most common, PBC context), anti-Sp140 (PBC context), anti-NXP-2/MJ (dermatomyositis context) |
| Primary clinical association | Primary biliary cholangitis (PBC) — the strongest and most consistent disease association for anti-Sp100/Sp140 |
| Other associations | Autoimmune hepatitis, PBC/AIH overlap syndrome, dermatomyositis (when anti-NXP-2 is the responsible antibody) |
| Clinical significance | More diagnostically meaningful than AC-7; anti-Sp100 and anti-Sp140 are clinically validated PBC markers |
AC-7: Few Nuclear Dots
| Feature | Details |
|---|---|
| Appearance | Classically ~1–6 discrete dots per cell (ICAP) |
| ICAP code | AC-7 |
| Associated antigens | p80-coilin and SMN complex proteins |
| Nuclear structure targeted | Cajal bodies (coiled bodies) and nuclear gems — structures involved in RNA processing |
| Disease association | Low positive predictive value for any specific disease (ICAP) |
| Testing limitation | Specific commercial immunoassays for p80-coilin/SMN complex antibodies are not routinely available |
| Clinical significance | Usually interpreted with symptoms, titer, and other findings; substantially less specific than AC-6 |
Important: The split between AC-6 and AC-7 is based on the laboratory's pattern call and any ICAP code provided — not on counting dots yourself. Because the ranges overlap at approximately 6 dots per cell, the lab's reported sub-type or ICAP code is the authoritative classification.
WHAT DOES "DISCRETE NUCLEAR DOTS" MEAN?
"Discrete nuclear dots" is the descriptive term laboratories use to report the nuclear dot ANA pattern. "Discrete" refers to the sharply defined, individually distinct appearance of the dots — each dot is separate and clearly bounded, unlike the more diffuse or granular staining of other ANA patterns.
When your report says "Discrete Nuclear Dots," it is describing the same finding as "nuclear dot pattern." The word "discrete" is a morphological descriptor telling you the dots are well-defined and individually distinguishable — it does not mean the finding is separate from your ANA result or indicate a specific severity level.
WHAT DOES "NUCLEAR DOT PATTERN HIGH" MEAN?
When a report states "nuclear dot pattern high" or shows the pattern alongside a high titer, the "high" refers to the ANA titer — the dilution at which antibodies remain detectable — not to the number of dots or the pattern's appearance.
| Titer with nuclear dot pattern | Clinical interpretation |
|---|---|
| 1:40 | Low positive — may be incidental; clinical correlation required |
| 1:80 | Low positive — requires clinical context; common even in healthy individuals |
| 1:160 | More likely to be clinically meaningful than very low titers; consider sub-type, symptoms, liver enzymes, and specific antibody testing |
| 1:320 | Higher positive — more concerning when AC-6 is present with cholestatic liver enzymes or PBC-specific antibodies |
| 1:640 and above | High titer — more clinically significant, especially with AC-6 and cholestatic pattern; titer alone does not diagnose disease |
For nuclear dot pattern, the most important interpretation variables are: AC-6 vs AC-7, titer, ALP/GGT pattern, AMA status, anti-Sp100/Sp140/gp210 results, and symptoms.
PRIMARY CLINICAL ASSOCIATION — PRIMARY BILIARY CHOLANGITIS (PBC)
The multiple nuclear dots pattern (AC-6) is one of the ANA patterns most specifically associated with primary biliary cholangitis (PBC) — a chronic autoimmune liver disease affecting the small bile ducts. A positive AC-6 pattern is a meaningful clue that should prompt PBC evaluation, especially when alkaline phosphatase or GGT is elevated, AMA is positive or unavailable, or symptoms such as itching and fatigue are present. The pattern alone does not diagnose PBC.
What is PBC? Primary biliary cholangitis (formerly called primary biliary cirrhosis) is an autoimmune condition in which the immune system attacks the small bile ducts inside the liver, causing progressive inflammation and scarring. It predominantly affects middle-aged women. Common symptoms include fatigue and itching (pruritus). Elevated alkaline phosphatase (ALP) and GGT are the characteristic biochemical findings. If diagnosed, first-line treatment is ursodeoxycholic acid (UDCA), and response is monitored with liver enzymes over time. Treatment is considered only if PBC is clinically diagnosed — a nuclear dot pattern alone is not a reason to start UDCA.
ANA patterns in PBC:
| ANA pattern | Antibody | Prevalence in PBC | Clinical significance |
|---|---|---|---|
| Multiple nuclear dots (AC-6) | Anti-Sp100, anti-Sp140 | ~25–30% of PBC patients | Highly specific for PBC; particularly useful when AMA is negative |
| Nuclear envelope/rim | Anti-gp210, anti-p62 | ~20–25% of PBC patients | Also PBC-associated; anti-gp210 may indicate more progressive disease |
| Speckled | Various | Common but less specific | Less diagnostically specific for PBC |
PBC evaluation components when nuclear dots are found:
| Component | Why it matters |
|---|---|
| Alkaline phosphatase (ALP) | Key cholestatic liver enzyme; persistent elevation is central to PBC evaluation |
| GGT | Supports cholestatic liver pattern when ALP is elevated |
| AMA / AMA-M2 | Primary PBC antibody; positive in most PBC cases |
| Anti-Sp100 / anti-Sp140 | PBC-specific nuclear body antibodies; especially useful when AMA is negative |
| Anti-gp210 | PBC-specific nuclear envelope antibody; may suggest more aggressive disease course |
| Bilirubin, albumin, platelets, INR | Help assess liver function and disease severity |
| Liver ultrasound | Helps exclude biliary obstruction or other structural liver disease |
| Hepatology referral | Appropriate when nuclear dots occur with cholestatic liver enzymes or PBC-specific antibodies |
Anti-Sp100: Anti-Sp100 targets the Sp100 nuclear antigen — a component of PML nuclear bodies. It is highly specific for PBC and is the antibody most commonly responsible for the AC-6 pattern in a liver disease context. Anti-Sp140, sometimes discussed in the broader PML nuclear body antibody context, may be included in some liver autoantibody profiles; in routine PBC evaluation, anti-Sp100 and anti-gp210 are more commonly emphasized clinically, especially when AMA is negative.
WHY NUCLEAR DOTS MATTER WHEN AMA IS NEGATIVE
Most PBC patients test positive for anti-mitochondrial antibody (AMA) — the primary PBC serological marker. However, a minority of PBC patients are AMA-negative. In that situation, PBC-specific ANA patterns and antibodies become especially important for diagnosis.
According to AASLD and EASL PBC guidelines, PBC can be established in AMA-negative patients when cholestatic liver enzyme elevation is present alongside PBC-specific ANA immunofluorescence patterns — such as the multiple nuclear dots pattern — or PBC-specific antibodies including anti-Sp100 and anti-gp210.
This is why a multiple nuclear dots (AC-6) finding should always be interpreted alongside ALP, GGT, AMA, anti-Sp100, anti-Sp140, anti-gp210, and symptoms such as itching or fatigue — particularly when AMA is unavailable or negative.
What if AMA or anti-Sp100 is positive but ALP and GGT are completely normal? A positive PBC-associated antibody without cholestatic liver enzyme elevation does not automatically diagnose PBC. In this situation, clinicians usually monitor liver enzymes over time and interpret the result with symptoms, imaging, and antibody profile. Current guidelines note that AMA alone without cholestatic biochemistry is not sufficient to diagnose PBC.
NUCLEAR DOT PATTERN VS NUCLEAR ENVELOPE/RIM PATTERN — A COMMON PBC CONFUSION
Both multiple nuclear dots and nuclear envelope/rim are PBC-associated ANA patterns, but they are different findings produced by different antibodies:
| Pattern | ICAP code | Appearance | PBC antibody context |
|---|---|---|---|
| Multiple nuclear dots | AC-6 | Multiple discrete dots within the nucleus | Anti-Sp100, anti-Sp140 — PBC-associated |
| Nuclear envelope/rim | AC-11 and related | Staining around the border of the nucleus | Anti-gp210, anti-p62 — PBC-associated; anti-gp210 may indicate more aggressive disease course |
| Centromere | AC-3 | Many dots (~40–80 per cell) at kinetochore positions | Anti-centromere — limited systemic sclerosis/CREST, not PBC |
Both nuclear dots (AC-6) and nuclear envelope/rim can be seen in PBC patients, and some patients may have both patterns. Neither individually diagnoses PBC — both require clinical and biochemical correlation.
WHAT DOES NUCLEAR DOT PATTERN MEAN FOR OTHER CONDITIONS?
While PBC is the primary association for AC-6, nuclear dot patterns can also be seen in:
| Condition | Notes |
|---|---|
| Autoimmune hepatitis (AIH) | Nuclear dot pattern may appear in AIH/PBC overlap syndrome |
| PBC/AIH overlap syndrome | One of the most clinically important contexts — both patterns and specific antibodies guide management |
| Dermatomyositis / inflammatory myopathy | When anti-NXP-2/MJ is the responsible antibody rather than anti-Sp100/Sp140 — different clinical context entirely |
| Sjögren's syndrome | Occasional association; usually accompanied by anti-SSA/Ro antibodies |
| Healthy individuals | AC-7 (few nuclear dots) may be seen as an incidental finding, particularly at low titer; ICAP notes AC-7 has low positive predictive value |
Anti-NXP-2/MJ and dermatomyositis: Anti-NXP-2/MJ is a myositis-associated antibody that can produce a multiple nuclear dots pattern on HEp-2 cells. It is most relevant when the patient has dermatomyositis or inflammatory myopathy features such as proximal muscle weakness, elevated CK or aldolase, characteristic rash (heliotrope rash, Gottron's papules), or dysphagia. In adults with confirmed inflammatory myopathy, anti-NXP-2 has been reported in association with malignancy risk, but a nuclear dot pattern alone does not indicate cancer — clinical context and specific antibody testing determine whether NXP-2 follow-up is appropriate.
SELECTED ICAP NUCLEAR PATTERN CODES RELEVANT TO NUCLEAR DOTS
Some laboratory reports use ICAP (International Consensus on ANA Patterns) AC-code nomenclature. Here are the codes most relevant when interpreting nuclear dot results:
| ICAP code | Pattern name | Description |
|---|---|---|
| AC-1 | Homogeneous | Uniform nuclear staining |
| AC-2, AC-3, AC-4, AC-5 | Speckled variants | Fine or coarse granular nuclear staining |
| AC-6 | Multiple nuclear dots | ~6–20 discrete nuclear dots per cell; PML nuclear bodies |
| AC-7 | Few nuclear dots | ~1–6 discrete nuclear dots per cell; Cajal bodies |
| AC-8, AC-9, AC-10 | Nucleolar patterns | Staining in nucleolus |
| AC-11 | Nuclear envelope/rim | Staining at nuclear border; PBC-associated |
| AC-3 | Centromere | ~40–80 dots at kinetochore positions; limited systemic sclerosis |
| AC-13 | PCNA | Proliferating cell nuclear antigen pattern |
| AC-29 | Dense fine speckled (DFS70) | DFS70/LEDGFp75 antibody |
Note: ICAP also lists additional pattern codes (AC-30, AC-31, and others) for less common patterns. If you see an AC code not listed here, refer to the ICAP website (anapatterns.org) for the full current classification.
SPECIFIC ANTIBODY FOLLOW-UP AFTER NUCLEAR DOT PATTERN
A positive nuclear dot pattern on ANA by IFA typically prompts follow-up with specific antibody tests:
| Follow-up test | Why ordered after nuclear dot pattern |
|---|---|
| Anti-Sp100 | Most common AC-6 antibody in PBC context; highly specific for PBC |
| Anti-Sp140 | Related PBC-associated PML nuclear body antigen; included in some liver autoantibody profiles |
| AMA / AMA-M2 | Primary PBC antibody; ordered to complete PBC workup |
| Anti-gp210 | PBC-specific nuclear envelope antibody; not a nuclear dot antibody, but ordered in PBC workup |
| ALP, GGT, bilirubin, ALT/AST | Biochemical liver context to determine if cholestatic pattern is present |
| Anti-NXP-2/MJ | Consider only if dermatomyositis or inflammatory myopathy features are present (muscle weakness, elevated CK) |
| Anti-coilin / SMN complex | AC-7/few nuclear dots context; specific commercial tests not routinely available |
WHEN SHOULD I WORRY ABOUT A NUCLEAR DOT PATTERN?
| Situation | Concern level | Suggested follow-up |
|---|---|---|
| AC-7 few nuclear dots + low titer + no symptoms | Low | Clinical correlation; usually not urgent; ICAP notes low positive predictive value |
| AC-6 multiple nuclear dots + normal ALP/GGT + no symptoms | Low-Moderate | Check AMA/AMA-M2, anti-Sp100/Sp140/gp210; monitor liver enzymes over time |
| AC-6 + elevated ALP or GGT | Moderate-High | PBC workup; hepatology referral |
| AC-6 + positive AMA or anti-Sp100 | Moderate-High | PBC evaluation; hepatology referral |
| AC-6 + elevated ALP/GGT + AMA negative | Moderate-High | Anti-Sp100, anti-Sp140, anti-gp210 testing; hepatology referral — this is a key scenario for AMA-negative PBC |
| Nuclear dots + muscle weakness + elevated CK/aldolase | Moderate-High | Myositis evaluation; anti-NXP-2/MJ testing; rheumatology referral |
| Nuclear dots + jaundice, severe itching, dark urine, pale stools | Higher urgency | Prompt medical evaluation |
MOST COMMON CLINICAL SCENARIOS
| Pattern | Most likely interpretation | Recommended next step |
|---|---|---|
| AC-6 + fatigue + elevated ALP | Probable PBC — classic presentation | Anti-Sp100, AMA, GGT, bilirubin; hepatology referral |
| AC-6 + normal ALP/GGT + no symptoms | Possible early/incidental finding; PBC not diagnosed from pattern alone | Check AMA/AMA-M2 and anti-Sp100/Sp140/gp210; repeat liver enzymes with clinician guidance |
| AC-6 + elevated ALP/GGT + positive anti-Sp100 or AMA | Strong PBC evaluation pattern | Hepatology referral |
| AC-6 + elevated ALP/GGT + AMA negative + anti-Sp100 positive | AMA-negative PBC pattern | Hepatology referral; UDCA evaluation |
| AC-7 + no symptoms + low titer | Likely incidental; low clinical significance | Clinical correlation; avoid overdiagnosis; no urgent action needed |
| AC-7 + autoimmune symptoms | Requires clinical context | Specific antibody testing; evaluate with other clinical findings |
| Nuclear dot pattern + high titer (1:320+) + liver symptoms | Clinically significant | Full PBC workup; hepatology evaluation |
| Nuclear dot pattern (AC-6) + positive anti-NXP-2 + muscle weakness | Dermatomyositis context | Myositis evaluation; muscle enzymes; rheumatology referral |
| Nuclear dot pattern + ANA 12 Plus Profile ordered | ANA 12 Plus Profile includes broad autoimmune markers but does not include PBC-specific anti-Sp100, anti-Sp140, anti-gp210, or AMA | If AC-6 is reported, order liver-focused follow-up separately: ALP, GGT, AMA/AMA-M2, anti-Sp100/Sp140, anti-gp210; hepatology evaluation if liver markers are abnormal |
FAQ about Nuclear Dot Pattern
-
What does nuclear dot pattern mean on an ANA test?
The nuclear dot pattern is a fluorescence pattern seen when a positive ANA by IFA test is examined under a fluorescent microscope. Instead of diffuse or granular staining, the nuclear dot pattern appears as a small number of sharply defined bright spots within the nucleus. These dots correspond to specific protein structures called nuclear bodies — particularly PML nuclear bodies (AC-6) or Cajal bodies (AC-7). The ICAP nomenclature divides the pattern into multiple nuclear dots (AC-6, classically ~6–20 dots per cell, most associated with primary biliary cholangitis through anti-Sp100 and anti-Sp140) and few nuclear dots (AC-7, classically ~1–6 dots per cell, with low positive predictive value for any specific disease). -
What does "discrete nuclear dots" mean?
"Discrete nuclear dots" is the descriptive term laboratories use to report the nuclear dot ANA pattern. "Discrete" refers to the morphological appearance — the dots are sharply defined and individually distinguishable under the microscope. When your report says "Discrete Nuclear Dots," it is describing the same finding as "nuclear dot pattern." The word "discrete" is not a clinical category or severity indicator. The clinically important question is whether the report specifies few or multiple nuclear dots — which determines the likely associated antibody and disease association. -
What does "few nuclear dots" mean on an ANA test?
Few nuclear dots refers to the AC-7 sub-type, where classically approximately 1–6 discrete dots are visible per nucleus under fluorescent microscopy. AC-7 is associated with antibodies to p80-coilin and SMN complex proteins that target Cajal bodies inside the nucleus. Importantly, ICAP notes that AC-7 has low positive predictive value for any specific disease. Specific commercial tests for p80-coilin/SMN antibodies are not routinely available. AC-7 at low titer with no symptoms is often an incidental finding that does not indicate a specific autoimmune disease. -
What does "multiple nuclear dots" mean on an ANA test?
Multiple nuclear dots refers to the AC-6 sub-type, where classically approximately 6–20 discrete dots are visible per nucleus under fluorescent microscopy. This pattern is produced by antibodies targeting PML nuclear bodies — most commonly anti-Sp100 and anti-Sp140 in the context of primary biliary cholangitis (PBC), or anti-NXP-2/MJ in the context of dermatomyositis or inflammatory myopathy. AC-6 is considered more clinically specific than AC-7. When this pattern is identified, follow-up testing with anti-Sp100, anti-Sp140, AMA, and liver enzyme evaluation is typically recommended. -
What diseases are associated with the nuclear dot ANA pattern?
The multiple nuclear dots pattern (AC-6) is most strongly associated with primary biliary cholangitis (PBC) — anti-Sp100 and anti-Sp140 are found in approximately 25–30% of PBC patients and are considered highly specific PBC markers, particularly useful when the primary PBC antibody (AMA) is negative. AC-6 can also be seen in autoimmune hepatitis and PBC/AIH overlap syndromes. When anti-NXP-2/MJ is the responsible antibody rather than anti-Sp100, the AC-6 pattern occurs in dermatomyositis context. The few nuclear dots pattern (AC-7) has low positive predictive value for any specific disease. -
What does "nuclear dot pattern high" mean?
"Nuclear dot pattern high" means a positive nuclear dot ANA pattern with a high titer — the "high" refers to the antibody concentration, not the number of dots. High titer means antibodies remain detectable at a high dilution of the blood sample (such as 1:320 or 1:640). A high-titer AC-6 nuclear dot pattern in a patient with elevated ALP/GGT and positive anti-Sp100 would be a clinically significant constellation pointing toward PBC evaluation. Titer alone does not diagnose disease — the sub-type, liver enzymes, and specific antibody results all matter. -
Is a nuclear dot pattern on ANA serious?
It depends on which sub-type is identified. AC-6 (multiple nuclear dots) at a significant titer warrants evaluation for primary biliary cholangitis, particularly with symptoms such as fatigue, itching, or elevated liver enzymes. PBC is very manageable when identified early — first-line treatment with ursodeoxycholic acid (UDCA) is effective and well-tolerated. AC-7 (few nuclear dots) with no symptoms and low titer is often an incidental finding with low positive predictive value. A nuclear dot pattern is not a medical emergency — it is a finding that guides what specific tests to do next. -
What is anti-Sp100 and why is it important?
Anti-Sp100 targets the Sp100 nuclear antigen, a protein found in PML nuclear bodies inside the nucleus. It is one of the main antibodies responsible for the AC-6 (multiple nuclear dots) pattern. Anti-Sp100 is considered highly specific for primary biliary cholangitis (PBC) and is clinically useful particularly in patients who are AMA-negative but have clinical and biochemical features suggesting PBC. Anti-Sp140, sometimes discussed in the broader PML nuclear body antibody context, may be included in some liver autoantibody profiles; in routine PBC evaluation, anti-Sp100 and anti-gp210 are the more commonly emphasized markers, especially when AMA is negative. A positive anti-Sp100 in the right clinical and biochemical context supports PBC evaluation. -
What is the difference between nuclear dot pattern and centromere pattern on ANA?
Both produce discrete dots on ANA by IFA, which can cause confusion. The key differences are: centromere pattern (AC-3) shows many more dots — ICAP describes approximately 40–80 per cell — corresponding to kinetochore/centromere staining at each chromosome, is associated with anti-centromere antibodies, and is linked to limited systemic sclerosis (CREST syndrome). Nuclear dot pattern (AC-6/AC-7) shows far fewer dots per nucleus and is associated with different antibodies (anti-Sp100, anti-Sp140) and different diseases (primarily PBC). The number of dots per nucleus and the clinical context are the key distinguishing factors. -
Can a nuclear dot pattern be seen in healthy people?
Yes — particularly the few nuclear dots pattern (AC-7) at low titer. ICAP notes that AC-7 has low positive predictive value for any specific disease, and it can be found as an incidental finding in people without autoimmune disease. The multiple nuclear dots pattern (AC-6) is more clinically meaningful, especially when paired with PBC-specific antibodies or cholestatic liver enzymes, but even AC-6 should not be interpreted without the full clinical picture including symptoms, liver enzymes, and specific antibody results. -
Does a nuclear dot pattern mean I have PBC?
No — a nuclear dot pattern does not diagnose PBC by itself. Multiple nuclear dots (AC-6) is a recognized PBC-associated pattern, and when anti-Sp100 or related PBC-specific antibodies are also positive, it is a meaningful pointer toward PBC evaluation. However, PBC diagnosis requires the combination of cholestatic liver enzyme elevation, PBC-specific antibodies (AMA, anti-Sp100, or anti-gp210), and sometimes liver histology. The pattern alone — without biochemical or serological support — is not sufficient to establish a PBC diagnosis.
Lab Results Explained and Tracked
Related Health Conditions
All Your Lab Results.
One Simple Dashboard.
Import, Track, and Share Your Lab Results Easily
Import, Track, and Share Your Lab Results
Import lab results from multiple providers, track changes over time, customize your reference ranges, and get clear explanations for each result. Everything is stored securely, exportable in one organized file, and shareable with your doctor—or anyone you choose.
Cancel or upgrade anytime
Related Biomarkers
Article Review & Sources
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We're committed to accuracy and transparency — see our editorial policy for details.
Laboratories
Bring All Your Lab Results Together — In One Place
We accept reports from any lab, so you can easily collect and organize all your health information in one secure spot.
Pricing Table
Gather Your Lab History — and Finally Make Sense of It
Finally, Your Lab Results Organized and Clear
Personal plans
$79/ year
Advanced Plan
Access your lab reports, explanations, and tracking tools.
- Import lab results from any provider
- Track all results with visual tools
- Customize your reference ranges
- Export your full lab history anytime
- Share results securely with anyone
- Receive 5 reports entered for you
- Cancel or upgrade anytime
$250/ once
Unlimited Account
Pay once, access everything—no monthly fees, no limits.
- Import lab results from any provider
- Track all results with visual tools
- Customize your reference ranges
- Export your full lab history anytime
- Share results securely with anyone
- Receive 10 reports entered for you
- No subscriptions. No extra fees.
$45/ month
Pro Monthly
Designed for professionals managing their clients' lab reports
- Import lab results from any provider
- Track lab results for multiple clients
- Customize reference ranges per client
- Export lab histories and reports
- Begin with first report entered by us
- Cancel or upgrade anytime
About membership
What's included in a Healthmatters membership
Import Lab Results from Any Source
See Your Health Timeline
Understand What Your Results Mean
Visualize Your Results
Data Entry Service for Your Reports
Securely Share With Anyone You Trust
Let Your Lab Results Tell the Full Story
Once your results are in one place, see the bigger picture — track trends over time, compare data side by side, export your full history, and share securely with anyone you trust.
Bring all your results together to compare, track progress, export your history, and share securely.
What Healthmatters Members Are Saying
We implement proven measures to keep your data safe.
At HealthMatters, we're committed to maintaining the security and confidentiality of your personal information. We've put industry-leading security standards in place to help protect against the loss, misuse, or alteration of the information under our control. We use procedural, physical, and electronic security methods designed to prevent unauthorized people from getting access to this information. Our internal code of conduct adds additional privacy protection. All data is backed up multiple times a day and encrypted using SSL certificates. See our Privacy Policy for more details.